| Pulmonary Arterial Hypertension |
1 |
1 |
| SGLT2 Inhibitor |
0 |
0.99 |
| Heart Failure (HF) |
0 |
0.74 |
| Type 2 Diabetes Mellitus |
0 |
0.68 |
| Hypertension |
0 |
0.54 |
| Cardiovascular Risk Management |
0 |
0.35 |
| Heart |
0 |
0.32 |
| Pulmonary Hypertension |
0 |
0.24 |
| Hospital |
0 |
0.16 |
| Chronic Kidney Disease |
0 |
0.12 |
| Patient Safety |
0 |
0.12 |
| Renal Failure |
0 |
0.12 |
| Renal Disease |
0 |
0.11 |
| Adverse Effects |
0 |
0.08 |
| Artery |
0 |
0.08 |
| Clinical Research |
0 |
0.08 |
| Kidney |
0 |
0.08 |
| Lung |
0 |
0.08 |
| Residency |
0 |
0.08 |
| Thorax |
0 |
0.08 |
| Healthcare and Medical Technology |
0 |
0.06 |